Yersinia enterocolitica and the chronic fatigue syndrome.
Swanink, C M, Stolk-Engelaar, V M, van der Meer, J W et al. · The Journal of infection · 1998 · DOI
Quick Summary
This study looked for signs that a bacterium called Yersinia enterocolitica might cause ME/CFS by testing blood samples from 88 ME/CFS patients and 77 healthy people. Researchers found that antibodies (immune markers) to this bacterium were equally common in both groups, suggesting this particular infection is unlikely to be a major cause of ME/CFS.
Why It Matters
Identifying infectious triggers has been central to ME/CFS research, and ruling out specific pathogens helps focus investigation on more plausible causative mechanisms. This work contributes to the evidence base preventing unnecessary directed antimicrobial therapies in ME/CFS patients.
Observed Findings
27% of CFS patients (24/88) had IgG antibodies to one or more YOPs versus 25% of controls (19/77)
4 CFS patients and 2 controls had both IgG and IgA antibodies to ≥2 different YOPs
Symptoms compatible with persistent Yersinia infection were found both in seropositive and seronegative CFS patients
No statistically significant difference in antibody prevalence between CFS and control groups
Inferred Conclusions
Yersinia enterocolitica is unlikely to play a major role in CFS aetiology
The presence of Yersinia antibodies does not distinguish CFS patients from healthy controls
Symptoms in CFS are not uniquely associated with serological evidence of Yersinia infection
Remaining Questions
Could Yersinia contribute to ME/CFS in specific genetic or immunological subgroups not captured in this study?
What other infectious or non-infectious triggers might explain the common symptoms between seropositive and seronegative patients?
Could regional variation in Yersinia prevalence affect applicability of these findings to other populations?
What This Study Does Not Prove
This study does not prove Yersinia plays no role in any ME/CFS subset, nor does it exclude other bacterial or viral cofactors. The cross-sectional serological design cannot establish temporal relationships or distinguish past from persistent infection definitively. Negative results in one population do not universally apply to all ME/CFS cohorts.